Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07384091

The Diagnostic Accuracy of Ankle Audiometry Performed With the B250 for Superior Canal Dehiscence Syndrome in Patients Affected by Pulsatile Tinnitus and/or Autophony Disorders

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Region Stockholm · Other Government
Sex
All
Age
18 Years – 64 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to learn if the ankle audiometry test performed with the B250 bone conduction transducer can identify patients with superior canal dehiscence syndrome from those without among subjects presenting with autophony (a hearing condition where you hear your own body sounds) and/or pulsatile tinnitus. The main question it aims to answer: • Can ankle audiometry performed with B250 identify the condition of superior canal dehiscence syndrome among patients with autophony and/or pulsatile tinnitus, with a significance level of 80% and power level of 15%? Study participants will undergo ankle audiometry testing with the B250 and the threshold in dB FL (at the ankle) for which the patient hears the sound in the target ear will be measured.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTAnkle audiometry performed with the B250 transducerCalibrated vibration stimulation with a frequency of 250 Hz is applied at the ankle with the B250 transducer starting at an intensity of 80 dB FL. An incremental increase/decrease in the intensity of the applied bone vibration stimulus is employed in a manner similar to that performed during a standard pure tone hearing test. This is done in order to find the threshold in dB FL (at the ankle) for which the patient hears the sound in the target ear (right) is measured. The maximum applied intensity at the ankle will be 140 dB FL.

Timeline

Start date
2026-02-01
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2026-02-03
Last updated
2026-02-03

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT07384091. Inclusion in this directory is not an endorsement.